
PubMed:21362567
Annnotations
c_corpus
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-5 | PR:Q5S006 | denotes | LRRK2 |
T2 | 0-5 | PR:000003033 | denotes | LRRK2 |
T3 | 0-5 | PR:Q5S007 | denotes | LRRK2 |
T4 | 59-73 | D004198 | denotes | susceptibility |
T5 | 59-73 | D004198 | denotes | susceptibility |
T10 | 106-125 | D010300 | denotes | Parkinson's disease |
T11 | 106-125 | D010300 | denotes | Parkinson's disease |
T14 | 153-157 | PR:Q9V853 | denotes | lack |
T15 | 180-185 | D006801 | denotes | human |
T16 | 298-306 | SO:0000109 | denotes | mutation |
T18 | 329-336 | 6308 | denotes | Leucine |
T17 | 329-336 | CHEBI:15603 | denotes | Leucine |
T20 | 329-336 | D007930 | denotes | Leucine |
T21 | 329-336 | CHEBI:25017 | denotes | Leucine |
T22 | 329-336 | D007930 | denotes | Leucine |
T19 | 329-336 | SO:0001437 | denotes | Leucine |
T23 | 337-341 | PR:Q9V3C5 | denotes | Rich |
T24 | 349-355 | D010770 | denotes | Kinase |
T25 | 359-364 | PR:Q5S006 | denotes | LRRK2 |
T26 | 359-364 | PR:000003033 | denotes | LRRK2 |
T27 | 359-364 | PR:Q5S007 | denotes | LRRK2 |
T28 | 366-370 | SO:0000704 | denotes | gene |
T29 | 399-407 | SO:0000109 | denotes | mutation |
T30 | 479-484 | PR:Q5S006 | denotes | LRRK2 |
T31 | 479-484 | PR:000003033 | denotes | LRRK2 |
T32 | 479-484 | PR:Q5S007 | denotes | LRRK2 |
T33 | 485-493 | SO:0000109 | denotes | mutation |
T34 | 601-608 | D004194 | denotes | disease |
T35 | 601-608 | D004194 | denotes | disease |
T36 | 622-626 | CHEBI:23888 | denotes | drug |
T38 | 764-773 | P37379 | denotes | synuclein |
T37 | 764-773 | D051843 | denotes | synuclein |
T42 | 774-781 | PR:000000001 | denotes | protein |
T39 | 774-781 | GO:0003675 | denotes | protein |
T43 | 774-781 | SO:0000104 | denotes | protein |
T40 | 774-781 | CHEBI:36080 | denotes | protein |
T41 | 774-781 | CHEBI:11122 | denotes | protein |
T46 | 830-839 | P55866 | denotes | caspase-3 |
T47 | 830-839 | Q8MJC3 | denotes | caspase-3 |
T48 | 830-839 | Q2PFV2 | denotes | caspase-3 |
T49 | 830-839 | Q08DY9 | denotes | caspase-3 |
T50 | 830-839 | Q5IS54 | denotes | caspase-3 |
T51 | 830-839 | Q8MKI5 | denotes | caspase-3 |
T52 | 830-839 | PR:000002312 | denotes | caspase-3 |
T53 | 830-839 | Q8MJU1 | denotes | caspase-3 |
T54 | 830-839 | Q60431 | denotes | caspase-3 |
T55 | 830-839 | P42574 | denotes | caspase-3 |
T56 | 830-839 | Q5IS99 | denotes | caspase-3 |
T57 | 830-839 | Q95ND5 | denotes | caspase-3 |
T58 | 830-839 | P70677 | denotes | caspase-3 |
T59 | 830-839 | P55213 | denotes | caspase-3 |
T45 | 830-839 | D053148 | denotes | caspase-3 |
T60 | 855-865 | GO:0008219 | denotes | cell death |
T63 | 911-928 | 5499 | denotes | hydrogen peroxide |
T64 | 911-928 | D006861 | denotes | hydrogen peroxide |
T65 | 911-928 | CHEBI:16240 | denotes | hydrogen peroxide |
T66 | 911-928 | D006861 | denotes | hydrogen peroxide |
T68 | 930-936 | C072553 | denotes | MG-132 |
T69 | 930-936 | CHEBI:75142 | denotes | MG-132 |
T70 | 930-936 | C072553 | denotes | MG-132 |
T72 | 942-959 | D016627 | denotes | 6-hydroxydopamine |
T73 | 942-959 | D016627 | denotes | 6-hydroxydopamine |
T74 | 942-959 | CHEBI:78741 | denotes | 6-hydroxydopamine |
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 0-5 | gene:120892 | denotes | LRRK2 |
T1 | 87-93 | disease:C3825627 | denotes | stress |
R1 | T0 | T1 | associated_with | LRRK2,stress |
Allie
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
SS1_21362567_1_0 | 106-125 | expanded | denotes | Parkinson's disease |
SS2_21362567_1_0 | 127-129 | abbr | denotes | PD |
SS1_21362567_1_1 | 186-198 | expanded | denotes | dopaminergic |
SS2_21362567_1_1 | 200-202 | abbr | denotes | DA |
SS1_21362567_2_0 | 329-357 | expanded | denotes | Leucine-Rich Repeat Kinase-2 |
SS2_21362567_2_0 | 359-364 | abbr | denotes | LRRK2 |
AE1_21362567_1_0 | SS1_21362567_1_0 | SS2_21362567_1_0 | abbreviatedTo | Parkinson's disease,PD |
AE1_21362567_1_1 | SS1_21362567_1_1 | SS2_21362567_1_1 | abbreviatedTo | dopaminergic,DA |
AE1_21362567_2_0 | SS1_21362567_2_0 | SS2_21362567_2_0 | abbreviatedTo | Leucine-Rich Repeat Kinase-2,LRRK2 |
UseCases_ArguminSci_Discourse
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-94 | DRI_Background | denotes | LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. |
T2 | 95-212 | DRI_Background | denotes | Studies of Parkinson's disease (PD) have been hindered by lack of access to affected human dopaminergic (DA) neurons. |
T3 | 213-451 | DRI_Approach | denotes | Here, we report generation of induced pluripotent stem cells that carry the p.G2019S mutation (G2019S-iPSCs) in the Leucine-Rich Repeat Kinase-2 (LRRK2) gene, the most common PD-related mutation, and their differentiation into DA neurons. |
T4 | 452-639 | DRI_Challenge | denotes | The high penetrance of the LRRK2 mutation and its clinical resemblance to sporadic PD suggest that these cells could provide a valuable platform for disease analysis and drug development. |
T5 | 640-782 | DRI_Outcome | denotes | We found that DA neurons derived from G2019S-iPSCs showed increased expression of key oxidative stress-response genes and α-synuclein protein. |
T6 | 783-985 | DRI_Background | denotes | The mutant neurons were also more sensitive to caspase-3 activation and cell death caused by exposure to stress agents, such as hydrogen peroxide, MG-132, and 6-hydroxydopamine, than control DA neurons. |
T7 | 986-1130 | DRI_Challenge | denotes | This enhanced stress sensitivity is consistent with existing understanding of early PD phenotypes and represents a potential therapeutic target. |
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 95-212 | DRI_Background | denotes | Studies of Parkinson's disease (PD) have been hindered by lack of access to affected human dopaminergic (DA) neurons. |
T2 | 213-451 | DRI_Approach | denotes | Here, we report generation of induced pluripotent stem cells that carry the p.G2019S mutation (G2019S-iPSCs) in the Leucine-Rich Repeat Kinase-2 (LRRK2) gene, the most common PD-related mutation, and their differentiation into DA neurons. |
T3 | 452-639 | DRI_Challenge | denotes | The high penetrance of the LRRK2 mutation and its clinical resemblance to sporadic PD suggest that these cells could provide a valuable platform for disease analysis and drug development. |
T4 | 640-782 | DRI_Outcome | denotes | We found that DA neurons derived from G2019S-iPSCs showed increased expression of key oxidative stress-response genes and α-synuclein protein. |
T5 | 783-985 | DRI_Background | denotes | The mutant neurons were also more sensitive to caspase-3 activation and cell death caused by exposure to stress agents, such as hydrogen peroxide, MG-132, and 6-hydroxydopamine, than control DA neurons. |
T6 | 986-1130 | DRI_Challenge | denotes | This enhanced stress sensitivity is consistent with existing understanding of early PD phenotypes and represents a potential therapeutic target. |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 106-115 | HP_0001300 | denotes | Parkinson |
DisGeNET5_variant_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
21362567-2#95#101#geners34637584 | 308-314 | geners34637584 | denotes | G2019S |
21362567-2#76#84#geners34637584 | 289-297 | geners34637584 | denotes | p.G2019S |
21362567-2#175#177#diseaseC0030567 | 388-390 | diseaseC0030567 | denotes | PD |
95#101#geners34637584175#177#diseaseC0030567 | 21362567-2#95#101#geners34637584 | 21362567-2#175#177#diseaseC0030567 | associated_with | G2019S,PD |
76#84#geners34637584175#177#diseaseC0030567 | 21362567-2#76#84#geners34637584 | 21362567-2#175#177#diseaseC0030567 | associated_with | p.G2019S,PD |
DisGeNET5_gene_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
21362567-3#27#32#gene120892 | 479-484 | gene120892 | denotes | LRRK2 |
21362567-3#83#85#diseaseC0030567 | 535-537 | diseaseC0030567 | denotes | PD |
27#32#gene12089283#85#diseaseC0030567 | 21362567-3#27#32#gene120892 | 21362567-3#83#85#diseaseC0030567 | associated_with | LRRK2,PD |